NCT07142278 · Phase 1 · NOT YET RECRUITING
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
DUVAX is an experimental vaccine designed to trigger the immune system to produce antibodies against amyloid-beta and tau, two proteins that build up in Alzheimer's disease. This Phase 1 trial is the earliest stage of human testing — focused on safety and immune response, not yet on whether it slows or prevents disease. Researchers are comparing two doses against a placebo in healthy adults ages 40 to 65.
You may qualify if
- Healthy males and non-pregnant, non-lactating females, 40-65 years old
- BMI between 18.0 and 32.0 kg/m²
- Medically healthy with no significant abnormalities in medical history, exam, labs, ECG, or MRI
- Signed informed consent
- Women of childbearing potential: negative pregnancy test and use of effective contraception
- Men: vasectomized or agree to use condoms / not donate sperm during the study period
You're excluded if
- Clinically significant medical or psychiatric illness that may affect safety or study results
- MRI abnormalities (e.g., infarcts, microbleeds, ARIA-E) or contraindications to MRI
- Significant lab abnormalities (e.g., liver, kidney, hematology) or positive HIV/HBV/HCV tests
- Uncontrolled blood pressure, abnormal heart rate, or prolonged QTc interval
- Recent serious illness, surgery, or investigational drug use within 30 days
- Prior amyloid-beta or tau immunotherapy within 1 year
- Use of immunosuppressive agents or chronic anticoagulants
- History of severe vaccine reactions, autoimmune disease, or significant allergies
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-10-22